Revised. Amendments from Version 2
==================================

In this version, the figures have undergone minor cosmetic changes.

Introduction
============

Since their discovery in 1975 by Cohen *et al*. ^[@ref-1]^, kinases are now one of the most established drug target families, second only to G-protein-coupled receptors (GPCRs). Most progress in kinase research has occurred in the last 25 years including the discovery of many new kinases ^[@ref-2],\ [@ref-3]^, identification of new isoforms of pre-existing kinases ^[@ref-4],\ [@ref-5]^, elucidation of new biological pathways, and identification of many new kinase-disease associations ^[@ref-6],\ [@ref-7]^. While kinases are well-validated anti-cancer targets ^[@ref-8]--\ [@ref-11]^, kinase inhibitors also have been pursued in cardiovascular ^[@ref-12]^, autoimmune ^[@ref-13]^, inflammatory skin and bowel ^[@ref-14]^, neurodegenerative ^[@ref-15]^, and renal disease programs ^[@ref-16]^. Most small-molecule kinase inhibitors target the ATP binding site of the kinase catalytic domain ^[@ref-11]^. The ATP binding region of the catalytic domain is highly conserved among protein kinases, which has important consequences for drug development. Achieving selectivity of a small molecule inhibitor against kinase off-targets to avoid adverse reactions can be a major hurdle. However, the cross reactivity of many chemotypes can also open opportunities to focus on other closely related kinases. Despite the high degree of conservation in the ATP binding site, reasonably selective inhibitors with favorable pharmacological properties can be developed ^[@ref-17]^. It is now common in discovery programs to profile inhibitors against an extensive set of kinase targets ^[@ref-18]^. These kinase-profiling efforts have generated valuable data, providing insight into selectivity and promiscuity of clinical inhibitors ^[@ref-19]--\ [@ref-21]^.

Medicinal chemists can benefit significantly from well-curated databases documenting chemical structure(s) with an experimentally measured biological activity. These structure and activity databases or SAR databases help to better understand drug-target interaction, which can assist in the design of potent and selective chemical inhibitors ^[@ref-22]--\ [@ref-25]^. A well populated, editable, easy to search and flexible SAR database is an integral part of the modern drug design process ^[@ref-26]^. SAR databases provide elementary insights to researchers, including:

1.  Target druggability: known small molecule binders are required to categorize a protein as druggable. High-affinity and non-promiscuous inhibitors are particularly valuable to establish druggability; and can be further validated using structure biology information. In many cases druggability can be inferred for new targets using homology models ^[@ref-27]^ where similarities can be mapped via sequences, pathways or functions. Examples include the Target Informatics Platform ( [TIP](http://www.eidogen.com/tip.php)) ^[@ref-28]^ and [Modbase](http://salilab.org/modbase) ^[@ref-29]^.

2.  Scaffold selectivity: the golden principle that applies is "less selective scaffolds have more undesirable side effects." A prior knowledge of selectivity profiles can help in making informed decisions on which chemotypes to pursue at the start of discovery programs ^[@ref-30]^. Organizing data by scaffold enables classic SAR analysis in which side-chain moieties can be evaluated and considered or avoided in lead optimization ^[@ref-31]^.

3.  Clinical molecules: it can be very helpful to see scaffold(s) or derivatives under the study of launched drugs. This enables medicinal chemists to associate therapeutic classes with active scaffolds.

4.  Development and validation of computational methods: well-curated datasets are very helpful in the development and refinement of computational methodologies. With a common set of data, computational researchers can also compare and contrast methods, providing additional validation ^[@ref-32]^.

5.  Virtual screening: high-quality, well-curated, standardized and annotated datasets are required to build predictive models for virtual screening as we have shown previously specifically for the Kinase Knowledgebase ( [KKB](http://www.eidogen-sertanty.com/kinasekb.php)) data ^[@ref-33]^.

Materials and Methods
=====================

The [KKB](http://www.eidogen-sertanty.com/kinasekb.php) is a database of biological activity data, structure-activity relationships, and chemical synthesis data focused on protein kinases. Since its inception in 2001, the [KKB](http://www.eidogen-sertanty.com/kinasekb.php) has grown steadily with quarterly updates each year. With more than two decades of high quality SAR data, the [KKB](http://www.eidogen-sertanty.com/kinasekb.php) represents one of the first kinase target specific databases of biological activity and chemical synthesis data from curated scientific literature and patents. The [KKB](http://www.eidogen-sertanty.com/kinasekb.php) contains a large number of kinase structure-activity data points (\>1.8M) reported in peer-reviewed literature covering journals and patents. The data have been curated from over 150 different journals reporting kinase inhibitors with activity data, with leading contributions from *J Med Chem*, *Bioorg Med Chem*, *Bioorg Med ChemLett* and *Euro J Med Chem*. In addition, the KKB contains data curated from patents/applications from WO, EP and US. The scientific information is curated from the published text using a combination of automatic and manual efforts.

A summary of the first quarter release for year 2016 (Q1-2016) is reported in [Table 1](#T1){ref-type="table"}. With the [Q1-2016 KKB release](http://www.eidogen-sertanty.com/kinasekb.php), there are total of 506 unique kinase targets with over 682K unique small molecules. A listing of few "hot" kinase targets with their inhibitors (data points) is reported in [Table 2](#T2){ref-type="table"}.

###### Eidogen-Sertanty Kinase Knowledgebase.

Summary Statistics -- Q1 2016 Release.

  ------------------------------------------------- -----------
  Articles covered:                                 2,780
  Patents and patent applications covered:          6,346
  Total Number of Bio-activity data points:         1,775,368
  Total Number of unique molecules:                 682,289
  Total Number of unique molecules w/ assay data:   337,491
  Total Number of assay protocols:                  32,462
  ------------------------------------------------- -----------

###### Eidogen-Sertanty Kinase Knowledgebase.

Data Points for Selected Targets-- Q1 2016 Release.

  ------------------------------------------------------------------------------------------------------------------
  Kinase\                                 Enzyme Assay      Cell-Based Assay                                  
  Classification                                                                                              
  ---------------------- ---------------- ----------------- ------------------ ------- ------- ------- ------ ------
  **Non-Receptor**\      Abl              **ABL1**          14750              4843    2177    4237    1836   1098
  **Tyrosine Kinases**                                                                                        

  Csk                    **CSK**          3792              1448               450     548     266     146    

  Fak                    **FAK/PTK2**     10311             4067               3863    2880    1306    1300   

  JakA                   **JAK3**         29550             8778               11456   1327    605     440    

  Src                    **SRC**          21936             8289               4480    3425    1473    747    

  **LCK**                23819            10514             6090               784     381     214            

  **FYN**                3125             873               151                28      11      7              

  Syk                    **SYK**          39426             17549              16774   1037    484     268    

  **ZAP70**              5951             2998              1013               5       2       2              

  Tec                    **ITK**          10131             3690               2197    219     83      113    

  **Receptor**\          EGFR             **EGFR**          34293              14684   6593    19731   9068   3321
  **Tyrosine Kinases**                                                                                        

  **ERBB2**              11182            5199              1756               7988    4115    1803           

  Eph                    **EPHA2**        2935              765                223     12      0       1      

  FGFR                   **FGFR1**        19582             8394               4149    8781    3345    1622   

  InsR                   **INSR**         4607              1293               1032    920     422     395    

  Met                    **MET**          27032             10406              9308    5147    2526    1983   

  PDGFR                  **PDGFRB**       14058             5889               2388    5426    2653    983    

  **FLT3/FLK2**          13082            3974              2830               10224   4386    2268           

  **KIT**                14991            5153              2527               7040    3339    2747           

  Tie                    **TEK**          9142              4306               2300    3122    1561    1360   

  Trk                    **NTRK1/TRKA**   8199              3207               2925    1743    814     563    

  VEGFR                  **KDR/FLK1**     55991             24821              13899   20317   9119    6541   

  **FLT1**               9963             4251              1116               864     432     197            

  **CMGC Kinases**       CDK              **CDK2**          33878              12695   10411   5344    1119   667

  **CDK5**               8227             3048              1714               18      3       3              

  GSK                    **GSK3B**        22950             7766               6992    2013    519     832    

  MAPK                   **MAPK14**       36067             16077              14270   6541    2373    2787   

  **MAPK1**              11286            3073              3081               2725    1064    1085           

  **MAPK10**             5725             1615              1610               96      48      23             

  **MAPK8**              6225             1803              1523               880     285     393            

  **MAPK11**             1162             196               100                0       0       0              

  **AGC Kinases**        AKT              **AKT1**          14601              6333    5794    6970    3064   2831

  DMPK                   **ROCK1**        9135              2052               3105    189     40      65     

  PKB                    **PDPK1**        9569              3765               2642    148     68      44     

  PKC                    **PRKCA**        10670             3528               2588    5477    669     510    

  **PRKCE**              3759             1494              1032               2       1       1              

  **CAMK Kinases**       CAMKL            **CHEK1**         13724              5192    5202    3140    220    1130

  MAPKAPK                **MAPKAPK2**     11041             4073               3747    1311    649     637    

  **MAPKAPK3**           2138             518               299                0       0       0              

  **Other Protein**\     AUR              **AURKA**         22646              7904    7034    1128    474    382
  **Kinases**                                                                                                 

  IKK                    **IKBKB**        7628              2978               3146    367     83      144    

  **CHUK/IKBKA**         2938             999               764                296     148     147            

  PLK                    **PLK1**         9181              3223               3480    2986    1364    888    

  STE                    **MAP2K1**       6340              2551               2045    1651    573     655    

  TKL                    **ILK**          360               180                172     581     253     80     

  **RAF1**               11302            5058              3378               1956    885     581            

  **BRAF**               26349            12169             8983               6726    2442    2106           

  **Other Non-**\        Lipid Kinases    **PIK3/PIK3CG**   29925              13438   10899   3525    1758   1217
  **Protein Kinases**                                                                                         

  **PIK3CA**             36168            16418             12448              3392    1310    1219           

  Nucleotide\            **TK1**          1106              301                339     2416    533     193    
  Kinases                                                                                                     

  **ADK**                1924             931               723                669     252     240            
  ------------------------------------------------------------------------------------------------------------------

Kinase inhibitors are biologically active small molecules and their activity refers to experimentally measured data on a given kinase target (in enzyme or in cell based assays), using predefined experimental protocols. After curation and standardization, these measured values together with related information are indexed in the [KKB](http://www.eidogen-sertanty.com/kinasekb.php). Each inhibitor entered in the [KKB](http://www.eidogen-sertanty.com/kinasekb.php) carries unique identifiers such as:

1.  Chemical information and biological information: unique structure IDs (MR_ID) are assigned based on unique canonical SMILES. In addition hand-drawn Cartesian coordinates are captured. Chemical compounds are associated with calculated chemical and physical properties.

2.  Biological target and assay protocol: biological targets are annotated by EntrezGeneID, UniProt ID, and HUGO approved names. An assay protocol includes detailed information pertaining to the experiments performed to measure the biological activity for the compound. Each protocol has a descriptive title and a unique set of keywords. Assays are categorized by assay format (biochemical, cell-based, etc.) following standards set forth by BioAssay Ontology (BAO) ^[@ref-34],\ [@ref-35]^. Kinase targets are classified by protein and non-protein kinases and protein kinases by the typical domain-based classification into group, family, etc. We are in the process of mapping KKB targets to the Drug Target Ontology ( [DTO](http://drugtargetontology.org/)), which is in development.

3.  Experimental bioactivity screening results. A bioactivity data point is a defined result/endpoint of a specified small molecule compound tested in a biological assay. The assay is defined in b); result type/endpoint captured include IC ~50~, K ~i~, K ~d~; the vast majority for biochemical and cell-based assays correspond to BAO definitions.

4.  Source reference: bibliographic information and unique identifiers for journal article and patents from which information related to the molecules was extracted include PubMedID, DOI, and standardized patent numbers. For journals, the KKB provides title, authors name, journal-name, volume, issues, and page numbers. For patents their titles, patent or patent application number (along with family members), inventor's names, assignee names, publication data and priority numbers are provided.

It is observed that a disease type can be related to multiple kinase groups, and several diseases can arise from a common set of kinase group ( [Table 3](#T3){ref-type="table"}) ^[@ref-6]^. In the [KKB](http://www.eidogen-sertanty.com/kinasekb.php), kinases are classified by protein and non-protein kinases with several sub-categories such as carbohydrate and lipid kinase and the typical protein kinase groups (such CMGC, CAMK, TK, TKL, RGC, AGC) and further sub-groups such as families. [DTO](http://drugtargetontology.org/) provides a functional and phylogenetic classification of kinase domains to facilitate navigation of kinase drug targets. [DTO](http://drugtargetontology.org/) is developed as part of the [Illuminating the Druggable Genome](https://commonfund.nih.gov/idg/index) (IDG) project. Here we make datasets freely available for the research community including to support efforts such as [IDG](https://commonfund.nih.gov/idg/index). We also offer to run our predictive models built using [KKB](http://www.eidogen-sertanty.com/kinasekb.php) data to support prioritization of drug targets.

###### Kinase-disease association in top therapeutic segments.

  ---------------------------------------------
  Disease Class       Kinase Group
  ------------------- -------------------------
  Cancer              AGC;atypical;CAMK;CK1;\
                      CMGC;RGC;STE;TK;TKL

  Diabetes            AGC;CMGC;TK

  Cardiovascular      AGC;CAMK;CMGC;TKL

  Hypertension        AGC;CAMK;RGC

  Neurodegeneration   AGC;CAMK;CMGC;CK1

  Inflammation        CMGC;STE;TKL

  Immunity            AGC;TK
  ---------------------------------------------

Kinase inhibitor datasets
=========================

The wealth of kinase inhibitor data presents opportunities for analysis as a whole or by integrating such data into various computational platforms to support development and validation of hypotheses of kinase inhibition. Several years ago, Eidogen-Sertanty made available 3880 pIC ~50~ data points across three kinase targets (ABL1, SRC, and AURKA -- [validation sets](http://www.eidogen.com/kinasednld.php)) to foster algorithm development and validation worldwide. With this data note, eight additional targets comprising inhibitors for therapeutically important classes: EGFR, CDK2, ROCK2, MAPK14 and PI3K (class I catalytic) ( [Table 4](#T4){ref-type="table"}) totaling \~258K data points (structure with standard results/endpoints such as IC ~50~, K ~i~ or K ~d~) and \~76K unique chemical structures now have been made available to further foster worldwide development, validation, and collaborative interaction (see KB_SAR_DATA_F1000.txt and KB_SAR_DATA_F1000.sdf files). These datapoints have been exported from the [KKB](http://www.eidogen-sertanty.com/kinasekb.php) and survey 1044 articles and 942 patents.

###### Important aspects about the selected targets.

  ----------------------------------------------------------------------------------------------------------------
  Kinase   Approved Name                  Class                Diseases Associated            Entrez\   Uniprot\
                                                                                              GeneID    ID
  -------- ------------------------------ -------------------- ------------------------------ --------- ----------
  EGFR\*   Epidermal Growth Factor\       Receptor Tyrosine\   NSCLC, Medullary Thyroid\      1956      P00533
           Receptor                       Kinase               Cancer, Breast Cancer,\                  
                                                               Neonatal Inflammatory Skin\              
                                                               and Bowel Disease                        

  CDK2     Cyclin-Dependent Kinase 2      Serine/Threonine\    Angiomyoma, Carbuncle          1017      P24941
                                          Kinase                                                        

  ROCK2    Rho-Associated, Coiled-Coil\   Serine/Threonine\    Colorectal Cancer, Penile\     9475      O75116
           Containing Protein Kinase 2    Kinase               Disease, Hepatocellular\                 
                                                               Carcinoma                                

  MAPK14   Mitogen-Activated Protein\     Serine/Threonine\    Acquired Hyperkeratosis,\      1432      Q16539
           Kinase 14                      Kinase               Prostate Transitional Cell\              
                                                               Carcinoma, Immunity-related\             
                                                               Diseases                                 

  PIK3CA   Phosphatidylinositol-4,5-\     Lipid Kinase         Colorectal Cancer, Actinic\    5290      P42336
           Bisphosphate 3-Kinase,\                             Keratosis                                
           Catalytic Subunit Alpha                                                                      

  PIK3CB   Phosphatidylinositol-4,5-\     Lipid Kinase         \-                             5291      P42338
           Bisphosphate 3-Kinase,\                                                                      
           Catalytic Subunit Beta                                                                       

  PIK3CD   Phosphatidylinositol-4,5-\     Lipid Kinase         Immunodeficiency 14,\          5293      O00329
           Bisphosphate 3-Kinase,\                             Activated PIK3-Delta\                    
           Catalytic Subunit Delta                             Syndrome                                 

  PIK3CG   Phosphatidylinositol-4,5-\     Lipid Kinase         Lichen Nitidus                 5294      P48736
           Bisphosphate 3-Kinase,\                                                                      
           Catalytic Subunit Gamma                                                                      
  ----------------------------------------------------------------------------------------------------------------

\*Afatinib, Erlotinib, Gefitinib, Lapatinib, Osimertinib, Vandetanib are US-FDA approved kinase inhibitors with EGFR as one of the valid targets.

The datasets cover a broad range of biochemical and cell based studies investigating kinase inhibition; and they represent a diverse collection of pharmaceutically active scaffolds. These scaffolds can be easily examined for selectivity and specificity for the given eight kinase targets. Additionally, they can be used to infer novel target-inhibitor relationships for kinases and compounds not included in these subsets.

Bibliographic information is reported in the files ArticleInfo_F1000.txt and PatentInfo_F1000.txt. Experimental procedure along with metadata information for targets including EntrezGeneIDs, assay format/type (biochemical/enzyme, cell based, etc), keywords, species, and cell lines used in cell-based data are stored in AssayProtocols_F1000 (txt and xml attached).

The [KKB](http://www.eidogen-sertanty.com/kinasekb.php) validation sets have a maximum contribution from EGFR with nearly \~54K inhibitor molecules. This is followed by \~43K inhibitors for MAPK14; CDK2 and PIK3CA each have \~39K inhibitors. [Figure 1](#f1){ref-type="fig"} depicts data point distributions for each kinase in the attached subset. Moreover, 84% of the data are from biochemical enzyme based assay experiments, and 16% of the data from cell-based assays (in [Figure 2](#f2){ref-type="fig"}). The datapoint measures include IC ~50~, K ~i~ and K ~d~ ( [Figure 3](#f3){ref-type="fig"}).

![Data point distributions for each kinase.](f1000research-5-10762-g0000){#f1}

![Data points share for each assay type.](f1000research-5-10762-g0001){#f2}

![Data points in various assay measures.](f1000research-5-10762-g0002){#f3}

Analysis of \~76K unique molecules for selectivity against targets reveals that \~64K inhibit only one kinase of the eight kinases extracted ( [Figure 4](#f4){ref-type="fig"}). Approximately 5K molecules show activity against two kinase targets, and \~3K molecules show activity against three kinases. A total of 79 molecules in the subset have some activity against all the eight kinase targets.

![Selectivity profile for data points.](f1000research-5-10762-g0003){#f4}

###### 

The file \'Datasets legends\' contains descriptions for each dataset.

###### 

Click here for additional data file.
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Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication).

Conclusions
===========

The [KKB](http://www.eidogen-sertanty.com/kinasekb.php) is available in various formats such as SQL, SDF and IJC format ( [Instant JChem](https://www.chemaxon.com/products/instant-jchem-suite/instant-jchem/)) as quarterly updates. Two mobile apps, [iKinase and iKinasePro](http://www.eidogen-sertanty.com/mobileapps.php) ^[@ref-25]^, are also available for download which enable basic search access into [KKB](http://www.eidogen-sertanty.com/kinasekb.php) content, including kinase inhibitor structures, biological data and references/patents. Simple substructure and exact structure [search access into the KKB](http://www.eidogen.com/kinasekb.php) is also available. We have extracted from the KKB \~258K structure activity data points and \~76K associated unique chemical structures across eight kinase targets and made these data freely available for download within this data note to foster algorithms development and validation [worldwide]{.ul}.

Data availability
=================

The data referenced by this article are under copyright with the following copyright statement: Copyright: © 2016 Sharma R et al.

Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication). <http://creativecommons.org/publicdomain/zero/1.0/>

F1000Research: Dataset 1. High quality, small molecule-activity for kinase research, [10.5256/f1000research.8950.d124591](http://dx.doi.org/10.5256/f1000research.8950.d124591) ^[@ref-36]^
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The paper describes Kinase Knowledgebase (KKB), i.e., a database containing structure-activity data on kinases. The current data note briefly presents the KKB Q1 2016 Release and the appended eight kinase data sets, which are made hereby publicly available. 

Kinases are valuable targets for many diseases, especially cancers. The subject is of real scientific. In general, the amount of bioactivity data, coming from various sources (scientific literature, high-throughput screening results, patents etc), is heterogeneous and a proper curation and standardization of the data can provide reliable activity points. These data may be employed in many ways as described by the authors. In my opinion, the main applications for a database such as KKB would be to build predictors to search the chemical space for new kinase inhibitors, and further to optimize the selectivity of kinase inhibitors. Currently, ChEMBL's ^1^ publicly available Kinase SARfari ( <https://www.ebi.ac.uk/chembl/sarfari/kinasesarfari>), provides a standard source for these tasks, covering about 532155 bioactivity data points i.e., version: 6.00- accessed June 20, 2016. This is less than one third of the 1.8 million KKB activity data point reported by the authors. In these circumstances, KKB might add valuable information for kinase research. Finally, the future analysis and employment of the eight data sets made freely available in the current note will provide a clearer view of the potential and versatility of KKB. 

There would be two minor observations: The methodology used to generate the data is described in the first paragraph in the section entitled "Kinase Knowledgebase (KKB)". In order to be more accessible for the reader, this paragraph should be encompassed in a separate section named "Materials and methods".In Table 2 there are three columns with repeated headers. In order to remove any doubts, I would recommend the authors to clarify this issue.   Otherwise, the data note is well written, kinases are indexed using the widely adopted Uniprot IDs and the references are updated.

I recommend this data note for indexation and would like the authors to address the minor observations.
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This article describes an overview of current kinase-related databases of significance, with particular focus on the contents of the Kinase Knowledgebase (KKB). The KKB has the largest repository of high-quality kinase activity data. Providing access to over ¼ million data points on several of the most important kinases allows for an exciting insight into the relevance of these validated drug targets and the diversity of compounds affecting them.  It is a promising trend that private companies are unlocking their proprietary data troves for the advancement of academic research. This is a nice Data Note that merits indexing in F1000Research.

A few minor typographical corrections: Table 2: Three of the column names seem to be duplicated.Table 2: It is unclear what the grey vs white rows represent in 'Kinase Classification' and 'Family' columns. If only for readability, perhaps these should alternate.Section 'Kinase inhibitor datasets' at the end of the first paragraph: The word 'respectively' is not needed.Section 'Kinase inhibitor datasets' 4 ^th^ paragraph, '\~54K inhibitors molecules': 'inhibitors' does not need to be plural.Figures 1 & 2:I would use the word 'Breakdown' instead of 'Breakup'.Figure 2: Are 'Cell-Free' and 'Animal Model' truly zero percent? If so, they should be excluded; if not, the fractional percent should be listed.'Conclusions': 'datanote' should be two words, to be consistent with the F1000 article type.
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